AbbVie Inc.

AbbVie is a biopharmaceutical company that discovers, develops, manufactures, and sells medicines and therapies. The company operates through a single global business segment covering therapeutic areas such as immunology, oncology, neuroscience, aesthetics, and eye care. Its key products include immunology medications such as Skyrizi, Rinvoq, and Humira; neuroscience therapies like Vraylar and Botox Therapeutic; oncology treatments including Imbruvica and Venclexta; and aesthetic offerings such as Botox Cosmetic and Juvederm fillers. AbbVie markets its products to physicians, healthcare providers, managed care organizations, hospitals, government agencies, and consumers. Its customers also include wholesale distributors, independent retailers, and specialty pharmacies.

The company distributes its products worldwide, maintaining company-owned distribution facilities and public warehouses. Its medicines are commercially available across North America, the European Union, Japan, and additional markets in South America, the Middle East, and Asia. In the United States, distribution relies primarily on independent wholesale distributors. The provided text notes that the company was incorporated in Delaware, but does not state a headquarters location.

Summary of the business section of AbbVie's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“AbbVie employed approximately 57,000 employees in over 70 countries as of December 31, 2025.”